Not yet recruiting
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
NCT07881432· Phase 3· Eli Lilly and Company· Source
Contact: Michelle Welch (principal investigator)
Not yet recruiting
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
NCT07919405· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
NCT07931547· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
NCT07919678· Phase 3· Pfizer· Source
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579· Phase 3· Eli Lilly and Company· Source
Contact: Michelle Welch (principal investigator)
Recruiting
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
NCT07282613· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336· Phase 3· Eli Lilly and Company· Source
Contact: Michelle Welch (principal investigator)
Active, not recruiting
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
NCT07477704· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582· Phase 3· Eli Lilly and Company· Source
Contact: Michelle Welch (principal investigator)
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Active, not recruiting
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932· Phase 2· Pfizer· Source
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
NCT07415954· Phase 2· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190· Phase 3· Eli Lilly and Company· Source
Contact: Michelle Welch (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011· Phase 3· Eli Lilly and Company· Source
Contact: Michelle Welch (principal investigator)
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931· Phase 3· Eli Lilly and Company· Source
Contact: Michelle Welch (principal investigator)
Active, not recruiting
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
NCT07215559· Phase 2· Eli Lilly and Company· Source
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Michelle Welch (principal investigator)
Active, not recruiting
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
NCT07215312· Phase 2· Eli Lilly and Company· Source
Active, not recruiting
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475· Phase 2· Eli Lilly and Company· Source
Contact: Michelle Welch (principal investigator)
Active, not recruiting
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT06401044· Phase 1/2· Amgen· Source
Active, not recruiting
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
NCT03811561· Phase 3· Novo Nordisk A/S· Source